Workflow
安必平: 股东减持股份计划公告

Summary of Key Points Core Viewpoint - Nanjing Qianjing plans to reduce its holdings in Guangzhou Anbiping Pharmaceutical Technology Co., Ltd. due to funding needs, with a total reduction not exceeding 1,677,265 shares, representing 1.79% of the company's total share capital [2][5]. Shareholder Holding Situation - As of the announcement date, Nanjing Qianjing holds 1,677,265 shares, accounting for 1.79% of the total share capital, which were acquired before the company's IPO and became tradable after August 20, 2021 [2][3]. Reduction Plan Details - Nanjing Qianjing intends to reduce its holdings through two methods: - A maximum of 935,676 shares (1.00% of total share capital) via centralized bidding - A maximum of 741,589 shares (0.79% of total share capital) through block trading - The reduction will take place within three months starting 15 trading days after the announcement [2][4]. Compliance and Commitments - Nanjing Qianjing has made commitments regarding its shareholding, including: - Adhering to lock-up agreements for shares held before the IPO - Ensuring that any reduction in shares within two years post-lock-up will not be below the issue price, adjusted for any corporate actions [3][4]. - The company will comply with relevant laws and regulations regarding share reductions and will disclose plans in advance [5].